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Background: Elderly patients are the fastest growing age group in end-stage renal failure. Data from overseas 
show that transplantation is a safe and reliable mode of treatment for this group of patients. However, local data 
about the outcome in these patients are lacking. The aim of this study was to determine and compare the outcomes 
of renal transplantation among elderly recipients and younger recipients.
Methods: Using the Organ Registry and Transplant System in Kwong Wah Hospital and Princess Margaret 
Hospital, adult patients who had undergone renal transplantation and who had been followed-up by the two 
medical units were recruited. They were divided into the control group (age < 60) and the elderly group (age ≥ 60) 
according to age at transplantation. The following data were collected for cross-sectional analysis: comorbid ill-
nesses, transplantation details, immunosuppressive therapy, incidence and severity of acute rejections, incidence of 
infection and malignancy, graft and patient survival, and causes of graft loss and death.
Results: A total of 324 episodes of transplantation were recorded (266 controls and 58 elderly). The incidence 
of acute rejection was higher in the control group (18% vs. 8.6%, p = 0.08). There was a trend towards higher 
incidence of infection and malignancy in the elderly group, though the difference did not reach statistical sig-
nificance. The graft survival rate was similar in the two groups, while the 5-year patient survival rate was worse 
in the elderly group (92.1% vs. 79.3%, p = 0.0058).
Conclusion: The transplantation outcomes in elderly recipients are satisfactory, and age per se should not be 
considered a contraindication to transplantation. [Hong Kong J Nephrol 2010;12(1):12–9]
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INTRODUCTION
The elderly population of Hong Kong is increasing. Ac-
cording to data from the Census and Statistics Department 
[1], the number of elderly aged ≥ 65 has risen from 
629,555 (10.1%) in 1996 to 852,796 (12.4%) in 2006. 
The accompanying social problems and burden on the 
health care system is thus of increasing concern.
According to the Hong Kong Renal Registry report 
[2], more and more elderly are placed on renal replace-
ment therapy. In 2004, 40.1% of patients newly recruited 
to the dialysis program were older than 60 years of age, 
which represents a substantial proportion. In terms of 
survival, transplantation is the preferred modality of renal 
replacement therapy. In the United States, renal trans-
plantations in patients older than 60 are associated with 
a 61% decrease in long-term death risk and an increase 
of 4 years in life expectancy, as compared to hemodialy-
sis [3]. Apart from the survival benefit, transplantations 
can offer better quality of life and are more cost-effective 
when compared with hemodialysis or peritoneal dialysis 
[4]. In the pre-cyclosporine era, the elderly were often 
rejected from qualifying for transplantation due to the 
poor graft survival and high mortality rate [5]. Thanks 
to improvements in immunosuppressant and anesthetic 
techniques, transplantations are now considered to be 
safe procedures, and the outcomes have improved dra-
matically. It has been advocated that age per se should 
no longer be a contraindication to transplantation. Some 
studies have reported that mortality and graft survival are 
worse in elderly patients compared to non-elderly patients, 
while others have contradicted such findings [6,7]. There 
is a lack of local data on the outcome of renal transplan-
tation in the elderly, so this retrospective study was 
conducted to compare the outcomes of renal transplan-
tation between elderly and younger recipients.
METHODS
The Organ Registry and Transplant System (ORTS) is a 
computer database system that records the transplant 
details of patients followed-up by the respective hospital. 
Target patients were retrieved by this system from Kwong 
Wah Hospital and Princess Margaret Hospital. All adult 
patients (age ≥18) who had undergone renal transplan-
tations during the study period (from July 1, 2000 to 
June 30, 2005) and who were followed-up in the medical 
unit of the corresponding hospital were included in this 
cohort study. Patients were divided into two groups ac-
cording to their age at the time of transplantation. Those 
who had undergone transplantation at < 60 years of age 
were classified into the control group, while those 
aged ≥ 60 were put in the elderly group. Basic demo-
graphic data such as age, sex, body weight, serum crea-
tinine level (the most updated one), cause of end-stage 
renal failure, duration of dialysis before transplantation, 
and duration of follow-up were recorded. Those who 
had not received renal replacement therapy before 
transplantation were recorded as preemptive transplant. 
Data for serum creatinine level were skipped for those 
who had graft loss and were recorded for those who died 
with functioning grafts. The presence of the following 
comorbid illnesses was documented: diabetes mellitus 
(DM), hypertension, ischemic heart disease, and cere-
brovascular accident (CVA). Transplantation details, 
including donor source (cadaveric or living), number of 
previous transplants, and transplant center, were obtained. 
The maintenance immunosuppressive regimen, including 
number, type and dosage of medications, was noted. Data 
were omitted for those who had primary non-function 
of the allograft. For those who were on dialysis or who 
died with functioning grafts, the immunosuppressive 
regimen just before the event was documented. The 
dosage of Myfortic (Novartis International AG, Basel, 
Switzerland) was converted to the equivalent dose of 
mycophenolate mofetil (MMF) to facilitate calculation. 
The usage and dosage of calcium channel inhibitor, 
which inhibits microsomal P450, was recorded.
The following primary outcomes of this study were 
recorded: incidence of acute rejection, infection requiring 
hospitalization, cytomegalovirus (CMV) infection, and 
malignancy. Presence of CMV infection was defined as 
positive pp65 antigenemia in association with clinical 
disease. Graft loss was defined as loss of renal function 
requiring the patient to return to dialysis. The incidence 
and causes of graft loss and death were documented.
Statistical methods
Continuous data between groups were compared by 
Student’s t test or Mann-Whitney test where appropriate. 
Categorical data were compared by χ2 test or Fisher’s 
exact test where appropriate. Graft and patient survival 
rates were analyzed by Kaplan-Meier curve, and log-
rank test was used to compare the outcomes between 
the two groups. All data are presented as mean ± standard 
deviation unless specified. A p value < 0.05 was con-
sidered statistically significant.
RESULTS
From July 1, 2000 to June 30, 2005, using the ORTS 
database, 120 episodes of renal transplantation were 
documented in Kwong Wah Hospital and 204 episodes 
in Princess Margaret Hospital (Table 1). During this 
period, 266 episodes (82.1%) involved recipients younger 
than 60 (mean age, 44.0 ± 9.9 years; range, 19–59 years), 
while 58 episodes (17.9%) involved recipients aged ≥ 60 
(mean age, 65.8 ± 4.6 years; range, 60–79 years).
The baseline demographic data revealed no signifi-
cant differences in sex, body weight, serum creatinine 
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level, and length of follow-up between the two age 
groups. Elderly patients had shorter duration of dialysis 
before transplantation (32.3 months vs. 18.4 months, 
p = 0.023). Chronic glomerulonephritis was the most com-
mon cause of end-stage renal failure in the control group, 
while DM and hypertension were the most common 
causes in the elderly group. Other causes of end-stage 
renal failure, in the control group, were obstructive 
uropathy (4 cases), interstitial nephritis (2 cases) and 
nephrocalcinosis (3 cases), and in the elderly group, 
obstructive uropathy (1 case). For the majority of the 
control group and all the patients in the elderly group, 
it was their first transplantation, with most being cadav-
eric transplantation performed in mainland China.
At the time of the study, the elderly group had a 
significantly higher prevalence of DM, ischemic heart 
disease and CVA. Most of the patients in both groups 
had hypertension. All patients were given dual or triple 
immunosuppressive therapy. The proportion of patients 
on dual or triple immunosuppressants was similar be-
tween the two groups (Table 2). Data for 13 patients 
(4.9%) in the control group were missing because their 
Table 1. Demographic characteristics, causes of end-stage renal failure, and transplant details of the two groups
 Control (n = 266) Elderly (n = 58) p
Age (yr) 44.0 ± 9.9 65.8 ± 4.6 –
Male sex 163 (61.3%) 31 (53.4%) 0.27
Body weight (kg) 63.4 ± 12.3 63.7 ± 11.5 0.86
Serum Cr (μmol/L) 116 ± 49.3 104.6 ± 44.2 0.11
Duration of dialysis before transplant (mo) 32.3 ± 2.3 18.4 ± 8.4 < 0.05
Length of follow-up after transplant (mo) 45.1 ± 5.1 41.5 ± 1.5 0.13
Causes of ESRF
 Chronic GN 116 (43.6%) 9 (15.5%) < 0.05
 DM 26 (9.8%) 15 (25.9%) < 0.05
 Polycystic kidney 13 (4.9%) 3 (5.2%) 0.57
 HT 12 (4.5%) 7 (12.1%) < 0.05
 Unknown 90 (33.8%) 23 (39.7%) 0.40
 Others 9 (3.4%) 1 (1.7%) 0.11
Premorbid diseases
 DM 72 (27.1%) 27 (46.6%) < 0.05
 HT 226 (85.0%) 53 (91.4%) 0.20
 IHD 13 (4.9%) 19 (32.8%) < 0.05
 CVA 9 (3.4%) 11 (19.0%) < 0.05
Transplantation details
 Cadaveric donor 254 (95.5%) 58 (100%) 0.09
 First transplant 239 (89.8%) 58 (100%) < 0.05
 Transplantation done in mainland China 224 (84.2%) 58 (100%) < 0.05
 Preemptive transplant 69 (25.9%) 27 (46.6%) < 0.05
Cr = creatinine; ESRF = end-stage renal failure; GN = glomerulonephritis; DM = diabetes mellitus; HT = hypertension; IHD = isch-
emic heart disease; CVA = cerebrovascular accident.
Table 2. Prevalence and dosage of different immunosuppressants among the two groups
 Prevalence Daily dosage (mg)
 Control Elderly p Control Elderly p
Triple therapy 203 (76.3%) 47 (81.0%) 0.44
Cyclosporin A 169 (66.8%) 51 (87.9%) 0.001 136.3 ± 37.4 127.0 ± 38.9 0.12
Prednisolone 239 (94.5%) 58 (100%) 0.052 6.2 ± 3.41 6.1 ± 3.6 0.88
Azathioprine 53 (20.9%) 10 (17.2%) 0.53 64.6 ± 17.3 65.0 ± 17.5 0.95
MMF/Myfortic 164 (64.8%) 37 (63.8%) 0.88 954.3 ± 303.7 907.9 ± 269.0 0.33
Tacrolimus 75 (29.6%) 6 (10.3%) 0.003 3.1 ± 1.7 3.1 ± 2.0 0.93
Diltiazem/Lercanidipine 114 (44.9%) 30 (51.7%) 0.35 187.2 ± 114.6 205.0 ± 111.2 0.45
Sirolimus 7 (2.8%) 0 (0%) 0.23
Everolimus 1 (0.4%) 1 (1.7%) 0.34
MMF = mycophenolate mofetil.
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transplantation had been done in mainland China and 
the details could not be retrieved. The use of tacrolimus 
was more prevalent in the control group (29.6% vs. 
10.3%, p = 0.003), while cyclosporin A was more 
prevalent in the elderly group (66.8% vs. 87.9%, 
p = 0.001). Comparing the two calcineurin inhibitors in 
all patients, cyclosporin was more frequently used than 
tacrolimus. The usage of prednisolone, azathioprine, 
MMF/Myfortic (Novartis International AG), calcium 
channel blocker, sirolimus and everolimus was similar 
between the two groups. The dosages of cyclosporin A 
and MMF were lower in the elderly group, although the 
differences were not statistically significant (Table 2). 
The dosages of prednisolone, azathioprine, tacrolimus 
and diltiazem were similar between the two groups.
Regarding adjuvant induction therapy, monoclonal 
antibodies were more frequently given to the control 
group (23.3% vs. 8.6%, p < 0.012), but the corresponding 
data were missing in many cases (41.7% in control group 
vs. 60.3% in elderly group). The prevalence of polyclonal 
antibody usage (22.6% vs. 22.4%, p = 0.98) or no adjuvant 
therapy (10.5% vs. 8.6%, p = 0.66) was similar between 
the two groups. There were five patients in the control 
group who were given combination induction therapy: 
three were given polyclonal plus monoclonal antibodies, 
and two were given polyclonal antibodies plus plasma-
pheresis. The results are summarized in Table 3.
Forty-eight patients (18.0%) in the control group 
and five (8.6%) in the elderly group experienced acute 
rejections. The incidence of biopsy-proven acute rejection 
was also lower in the elderly group (12.0% vs. 3.4%, 
p = 0.053). The numbers of acute rejections per patient in 
the control group and the elderly group were 0.22 and 0.1, 
respectively. The differences were, however, not statisti-
cally significant (Table 4). A large proportion of rejections 
were diagnosed clinically without renal biopsy (Table 5).
Regarding the incidence of infections, the elderly 
group was observed to have more infections requiring 
hospitalizations (Table 4). One hundred and fifty-eight 
patients (59.4%) in the control group and 37 patients 
(63.8%) in the elderly group had at least one such ad-
mission, while 80 patients (30.1%) in the control group 
and 28 patients in the elderly group (48.2%) experienced 
at least two admissions as a result of infections 
(p = 0.008). There was a trend towards higher incidence 
of CMV infection in the elderly group (18.4% vs. 24.1%, 
p = 0.32) post transplantation. More patients in the el-
derly group developed malignancy (3.0% vs. 6.9%, 
p = 0.15). The following eight malignancies in the control 
group were found: two post-transplant lymphoproliferative 
disease, one carcinoma of breast, one carcinoma of thyroid, 
one renal cell carcinoma, one acute myeloid leukemia, 
one carcinoma of ovary and one metastatic adenocarci-
noma of unknown primary origin. Four patients in the 
elderly group had malignancies post transplantation: one 
transitional cell carcinoma of the urinary tract, one post-
transplant lymphoproliferative disease, one carcinoma of 
colon and one carcinoma of lung (Table 4).
Table 3. Comparison of adjuvant induction therapy between the 
two groups
 Control Elderly p
Polyclonal antibodies 60 (22.6%) 13 (22.4%) 0.98
Monoclonal antibodies 60 (23.3%) 5 (8.6%) 0.012
Unknown 111 (41.7%) 35 (60.3%) 0.01
No adjuvant therapy 28 (10.5%) 5 (8.6%) 0.66
Combination 5 (1.9%) 0 0.37
Table 4. Incidence of acute rejection, infection requiring hospitalization, cytomegalovirus infection and malignancy of the two groups
 Control Elderly p
Incidence of AR 48 (18.0%) 5 (8.6%) 0.08
Incidence of biopsy-proven AR 32 (12.0%) 2 (3.4%) 0.053
Number of ARs per patient 0.22 0.10 0.081
Incidence of infection requiring hospitalization
 ≥ 1 episode 158 (59.4%) 37 (63.8%) 0.54
 ≥ 2 episodes 80 (30.1%) 28 (48.2%) 0.008
 ≥ 3 episodes 44 (16.5%) 13 (22.4%) 0.29
Incidence of CMV infection 49 (18.4%) 14 (24.1%) 0.32
Malignancy 8 (3.0%) 4 (6.9%) 0.15
AR = acute rejection; CMV = cytomegalovirus.
Table 5. Comparison of rejection grade between the two groups
 Control Elderly
Banff grade I 18 (31%) 0
Banff grade II 6 (10.3%) 1 (16.7%)
Humoral 2 (3.4%) 1 (16.7%)
Banff grade I + humoral 2 (3.4%) 0
Unknown/grading not clearly stated 11 (19%) 0
Biopsy not done 19 (32.8%) 4 (66.7%)
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Graft survival
Patients who do not require regular renal replacement 
therapy were defined as having survived graft. For the 
whole cohort of 324 patients, the overall 1-year and 
5-year death-censored graft survival rates were 95.4% 
and 91.7%, respectively (Figure 1). The death-censored 
1-year and 5-year graft survival rates, respectively, were 
94.4% and 90.6% in the control group, and 100% and 
96% in the elderly group. There were no differences 
between the two groups (p = 0.297 and p = 0.178, respec-
tively). The main causes of graft loss in the control group 
were death with functioning graft (39%), primary non-
function (9.8%), acute rejection (9.8%), vascular prob-
lem (9.8%), and chronic allograft dysfunction (9.8%). 
The main causes of graft loss in the elderly group were 
death with functioning graft (83.3%), chronic allograft 
dysfunction (8.3%), and allograft infection (8.3%).
The overall 1-year and 5-year patient survival rates 
for the whole cohort were 95.4% and 89.8%, respectively 
(Figure 2). The 1-year patient survival rates were 95.5% 
and 94.8% for the control group and elderly group, 
respectively. However, the 5-year patient survival rate was 
better in the control than in the elderly group (92.1% vs. 
79.3%, p = 0.0058).
The main causes of death in the control group were 
infection (47.6%), unknown (23.8%), cardiovascular 
(14.3%), and malignancy (14.3%) (Table 6). The main 
causes of death in the elderly group were infection 
(66.7%), unknown (25.0%), and malignancy (8.3%). There 
were no statistically significant differences detected.
DISCUSSION
With this background on the use of immunosuppressive 
agents in mind, we found that the incidence of acute 
rejection and biopsy-proven acute rejection was lower 
in the elderly group than in the control group. The results 
are similar to those of a retrospective study by Meier-
Kriesche et al [8] of 73,707 patients who had undergone 
primary renal transplantation between 1988 and 1997. 
The incidence of acute rejection at 6 months decreased 
from 28% in the youngest age group to 19.7% in the 
oldest age group. In a retrospective review [9], 1,095 
patients were divided into four groups according to their 
age (18–49, 50–59, 60–64, ≥ 65). The incidence of acute 
rejections showed a decreasing trend across the 
age groups (34.7%, 25.2%, 27.9%, 23.6%; p = 0.09). 
Friedman et al [10] reported similar findings when 16 
patients aged ≥ 60 were compared with 230 patients 
aged < 60. The overall incidence of acute rejections in the 
first 90 days was higher in the younger group (33.8% vs. 
6.3%, p = 0.001).
The observed tendency for older patients to develop 
less acute rejections could, hypothetically, be related to 
the immunological change with aging that renders the 
immune system less active [11]. At the molecular level, 
aging is associated with a decrease in T cell proliferation 
in response to T cell receptor- and co-stimulus-mediated 
stimulation [12]. The level of interleukin-2, an important 
cytokine in T cell activation, was also found to decrease 
with age [13]. Thus, as suggested in the current study, 
the incidence and severity of acute rejections should be 
lower in the elderly. On these grounds, one may argue 
that immune senescence may speak for a reduction in 



























































Figure 2. Kaplan-Meier curve of patient survival.
Table 6. Comparison of causes of death between the two groups
 Control Elderly p
Infection 10 (47.6%) 8 (66.7%) 0.24
Cardiovascular 3 (14.3%) 0 0.26
Malignancy 3 (14.3%) 1 (8.3%) 0.56
Unknown 5 (23.8%) 3 (25%) 0.60
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In this study, the incidence of infection requiring 
hospital admission was higher in the elderly group. The 
difference becomes more prominent when the frequency 
is taken into consideration. In other words, elderly pa-
tients tend to have more infective complications than 
younger patients. Similar findings have been reported in 
the literature. Trouillhet et al [14] compared 40 patients 
aged ≥ 65 and another 40 aged < 65 who had undergone 
renal transplantation. The incidence of infection was 80% 
in the elderly group and 32% in the younger group, with 
an odds ratio of 5, and a 95% confidence interval of 1.6 
to 20. The proposed rationale behind such an observation 
was the depressed immune system in the elderly.
CMV infection was more frequently observed 
among elderly transplant recipients (18.4% vs. 24.1%, 
p = 0.32) in the present study. This echoed the findings 
of Moreso et al [15] where the incidence of CMV infec-
tion was 29.3% in the elderly compared with 22–29% in 
the younger adults. In this study, the serology status of 
CMV for donors and recipients were not included as a 
result of incomplete data, so it was difficult to conclude 
whether or not age alone is a risk factor for CMV infection. 
CMV infection is associated with many adverse outcomes, 
including increase in acute rejections, decrease in graft 
and patient survival, and predisposition to infections and 
malignancy [16]. It is therefore desirable to detect and 
treat the disease early to improve the outcome of transplant 
recipients.
The overall incidence of malignancy was 3.7% and 
was slightly higher in the elderly group (3.0% vs. 6.9%, 
p = 0.15). Similar results were recently reported by 
Imao et al [17]. In their study, the overall incidence of 
malignancy was 6.8% (25/366), and age was identified 
as a risk factor for malignancy (hazard ratio = 1.562; 
95% confidence interval = 1.089–2.240; p = 0.0155). One 
of the possible explanations is age-related decline in 
immune surveillance, leading to the accumulation of 
cellular and DNA mutations, and increasing the risk 
of malignancy development [18]. Another reason 
would be related to exposure to oncogenic viruses in 
the elderly [19].
The overall 1-year and 5-year graft survival rates in 
the present study were 95.4% and 91.7% (death cen-
sored), respectively. The results are comparable to local 
data [2], where the 1-year and 5-year graft survival rates 
are 92.5% and 84.4% (death censored), respectively. 
The graft survival rate is better than in a previous 
larger-scale study [20]. In that review, the author pooled 
data from the Collaborative Transplant Study [21], 
United States Renal Data System annual report 1996 
[22], United States Network for Organ Sharing and 
Division of Organ Transplantation 1994 report [23], UK 
Transplant Services Special Authority newsletter [24] 
and combined series single center data and determined 
the overall graft survival rate to be 74% at 1 year and 
57% at 5 years. More recent data from the United States 
Renal Data System [25] showed that the 1-year graft 
survival rate was 89.5% in 2003 and 65.9% in 1999.
We have demonstrated that graft survival in the el-
derly is comparable to that in younger patients. Raviňa 
et al [26] reported that graft survival is not inferior in the 
elderly when death with a functioning graft was censored 
in the analysis. Humar et al [27] also revealed no signifi-
cant difference in the death-censored 5-year graft sur-
vival rate in the elderly compared to younger patients.
The main cause of graft loss in the elderly in the cur-
rent study was death with a functioning graft. This result 
was consistent with a study in a larger series where 56.5% 
of graft loss was due to death with a functioning graft 
among elderly patients [11]. Although the results of graft 
survival in this study seemed to be superior to those of 
other countries, we should interpret them with great care 
because the majority of the transplants were performed 
in mainland China, where donor information including 
donor age and human leukocyte antigen typing were not 
available for analysis. It is suggested that both factors 
are important determinants of graft survival [28,29].
The overall 1-year and 5-year patient survival rates 
were 95.4% and 89.8% in this study. This finding was 
comparable to the local registry data [2] where the 1-year 
and 5-year patient survival rates for cadaveric kidney 
transplant recipients were 96.1% and 91.2%, respectively. 
The results were also similar to figures reported in the 
United States [25], where the 1-year and 5-year patient 
survival rates were 94.6% and 79.3%, respectively.
In this study, the 5-year survival rate was lower in the 
elderly group (79.3% vs. 92.1%, p = 0.0058), while the 
1-year survival rate was similar. Oniscu et al [9] reported 
5-year survival rates of 81–91% in the younger versus 
59–66% in the elderly patients (p < 0.001), and Giblin 
et al [30] reported similar findings of 87% versus 60% 
(p < 0.001). This observation can be explained by the 
more frequent association with comorbid illnesses in the 
elderly. Although the mortality rate in the elderly was 
higher than in younger adults, the outcome was still 
better than those who were on dialysis [31,32].
There was a trend in this study towards a higher 
proportion of patients in the elderly group dying of 
infection compared with the control group (45.5% vs. 
66.7%, p = 0.24). This proportion was higher than in 
previously reported series. Gill et al [33] analyzed the 
causes of death in 4,741 patients and found that infection 
accounted for only 17%. In another study involving 
1,567 patients, the cause of death due to infection in the 
elderly group (age > 65) was 22%, versus 16% in the 
younger age group [32]. One can argue that the small 
sample size and short duration of follow-up in the present 
study may have affected the results, but over-immuno-
suppression is another possible explanation. Some 
studies have reported a changing pattern of causes of 
death among transplant recipients as a function of the 
length of follow-up. Jassal et al [34] demonstrated that 
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mortality due to infection decreased from 40.1% to 11.5% 
from the first year to 5–10 years. At the same time, mor-
tality due to cardiac disease and malignancy rose from 
24.3% and 5.0% in the first year to 29.4% and 23.7% 
at 5–10 years. Since the mean duration of follow-up in 
the current study was 43 months, the longer-term out-
come at 5–10 years may have been different.
The present study has several limitations. First, the 
samples were collected from two hospitals in Hong Kong, 
which may not be representative of the whole picture 
in this locality. In addition, the average duration of 
follow-up was less than 4 years, and may not be able 
to determine the long-term outcomes of these patients. 
More precise data on the immunosuppressants used, such 
as cumulative dosage of steroid, drug level of calcineurin 
inhibitors, and combination of immunosuppressants, may 
enable a more precise correlation with outcome. Most 
of the patients had undergone transplantation in mainland 
China, rendering their perioperative data not generally 
available. Important parameters such as donor age, donor 
human leukocyte antigen typing, details of induction 
therapy and postoperative clinical course were thus miss-
ing in most of these cases. These parameters are also 
vital in the precise analysis of patient outcomes. Quality 
of life is another aspect we would like to investigate, 
but which was outside the scope of the current study.
This study found that elderly renal transplant re-
cipients were more frequently associated with comor-
bidities including DM, ischemic heart disease and CVA. 
The use of cyclosporin A was more prevalent in the 
elderly than in the control group. The incidence of acute 
rejection was lower, while the incidence of infection 
and malignancy was higher in the elderly group. Graft 
survival in the elderly group was comparable to that in 
the control group, especially when death with function-
ing graft was censored. It is thus intriguingly to specu-
late that there is some sort of senescence of our immune 
system as aging occurs. As a result, the elderly do not 
experience graft rejection as often as younger patients, 
but they do have a higher incidence of complications of 
over-immunosuppression, namely infections and ma-
lignancy. The optimal immunosuppressive therapy for 
elderly renal transplant recipients may thus be different 
from that which is universally recommended for all, and 
needs to be specifically addressed.
REFERENCES
1. Census and Statistical Department. Statistical Table. Population by 
Age Group, 1996, 2001 and 2006. Available at http://www.censtatd.
gov.hk/hong_kong_statistics/statistical_tables/index_t.jsp?charset
ID=1&subjectID=1&tableID=137 [Date accessed: March 15, 
2007]
2. Ho YW, Chau KF, Leung CB, Choy BY, Tsang WK, Wong PN, 
et al. Hong Kong Registry Report 2004. Hong Kong J Nephrol 
2005;7:38–46.
3. Wolfe RA, Ashby UB, Milford EL, Ojo AO, Ettenger RE, Agodoa 
LY, et al. Comparison of mortality in all patients on dialysis, patients 
on dialysis awaiting transplantation and recipients of a first cadaveric 
transplant. N Engl J Med 1999;341:1725–30.
4. Cameron JI, Whiteside C, Katz J, Devins GM. Differences in quality 
of life across renal replacement therapies: a meta-analytic 
comparison. Am J Kidney Dis 2000;35:629–37.
5. Winkelmayer WC, Weinstein MC, Mittleman MA, Glynn RJ, Pliskin 
JS. Health economic evaluations: the special case of end-stage renal 
disease treatment. Med Decis Making 2002;22:417–30.
6. Ismail N, Hakim RM, Helderman JH. Renal replacement therapies 
in the elderly: Part II. Renal transplantation. Am J Kidney Dis 
1994;23:1–15.
7. Doyle SE, Matas AJ, Gillingham K, Rosenberg ME. Predicting 
clinical outcome in the elderly renal transplant recipient. Kidney Int 
2000;57:2144–50.
8. Meier-Kriesche HU, Ojo A, Hanson J, Cibrik D, Lake K, Agodoa 
LY, et al. Increased immunosuppressive vulnerability in elderly 
renal transplant recipients. Transplantation 2000;69:885–9.
9. Oniscu GC, Brown H, Forsythe JL. How old is old for trans-
plantation? Am J Transplant 2004;4:2067–74.
10. Friedman AL, Goker O, Kalish MA, Basadonna GP, Kliger AS, Bia 
MJ, et al. Renal transplant recipients aged over 60 have diminished 
immune activity and a low risk of rejection. Int Urol Nephrol 
2004;36:451–6.
11. Wick G, Grubeck-Loebenstein B. The aging immune system: 
primary and secondary alterations of immune reactivity in the 
elderly. Exp Gerontol 1997;32:401–13.
12. Hodes JR. Molecular alterations in the aging immune system. J Exp 
Med 1995;182:1–3.
13. Globerson A. T lymphocytes and aging. Int Arch Allergy Immunol 
1995;107:491–7.
14. Trouillhet I, Benito N, Cervera C, Rivas P, Cofán F, Almela M, 
et al. Influence of age in renal transplant infections: cases and 
controls study. Transplantation 2005;80:989–92.
15. Moreso F, Ortega F, Mediluce A. Recipient age as a determinant 
factor of patient and graft survival. Nephrol Dial Transplant 2004;
19 (Suppl 3):16–20.
16. Fishman JA, Emery V, Freeman R, Pascual M, Rostaing L, Schlitt 
HJ, et al. Cytomegalovirus in transplantation—challenging the status 
quo. Clin Transplant 2007;21:149–58.
17. Imao T, Ichimaru N, Takahara S, Kokado Y, Okumi M, Imamura R, 
et al. Risk factors for malignancy in Japanese renal transplant 
recipients. Cancer 2007;109:2109–15.
18. Burns EA, Leventhal EA. Aging, immunity, and cancer. Cancer 
Control 2000;7:513–22.
19. Muller AM, Ihorst G, Mertelsmann R, Engelhardt M. Epidemiology 
of non-Hodgkin’s lymphoma: trends, geographic distribution, and 
etiology. Ann Hematol 2005;84:1–12.
20. Cameron JS. Renal transplantation in the elderly. Int Urol Nephrol 
2000;32:193–201.
21. Opelz G. Factors influencing kidney graft survival in Latin America. 
Collaborative Transplant Study. Transplant Proc 1999;31:2951–4.
22. United States Renal Data System. Annual Data Report 1996 and 
Reference Tables. Available at http://www.usrds.org/adr_1996.htm 
[Date accessed: March 15, 2007]
23. United States Network for Organ Sharing and Division of Organ 
Transplantation 1994 Report (1988–1993). Bethesda, MD: Bureau 
of Health Services Development, US Department of Health and 
Human Services, 1994.
24. Belger M. UK Transplant Services Special Authority Newsletter. 
Bristol: UKTSSA, 1998.
Hong Kong J Nephrol • April 2010 • Vol 12 • No 1 19
 Renal transplantation outcomes in elderly patients
25. United States Renal Data System. Annual Data Report 2006 
Reference Tables. Available at http://www.usrds.org/reference.htm 
[Date accessed: March 15, 2007]
26. Raviňa FO, Martinez MR, Gude F, González-Juanatey JR, Valdés 
F, Sánchez-Guisande D. Renal transplantation in elderly: does 
patient age determine results? Age Aging 2005;34:583–7.
27. Humar A, Denny R, Matas AJ, Najarian JS. Graft and quality of 
life outcomes in older recipients of a kidney transplant. Exp Clin 
Transplant 2003;1:69–72.
28. Pugliese O, Quintieri F, Mattucci DA, Venettoni S, Taioli E, Costa 
AN. Kidney graft survival in Italy and factors influencing it. Prog 
Transplant 2005;15:385–91.
29. Zhou YC, Cecka JM. Effect of HLA matching on renal transplant 
survival. Clin Transpl 1993:499–510.
30. Giblin L, Hollander M, Little D, Hickey D, Donohoe J, Walshe JJ, 
et al. Renal transplantation in the elderly—the Irish experience. 
Ir J Med Sci 2005;174:9–13.
31. Johnson DW, Herzig K, Purdie D, Brown AM, Rigby RJ, Nicol DL, 
et al. A comparison of the effects of dialysis and renal transplantation 
on the survival of older uremic patients. Transplantation 2000;
69:794–9.
32. Bonal J, Cleris M, Vela E. Transplantation versus haemodialysis in 
elderly patients. Nephrol Dial Transplant 1997;12:261–4.
33. Gill JS, Abichandani R, Kausz AT, Pereira BJ. Mortality after kidney 
transplant failure: the impact of non-immunologic factors. Kidney Int 
2002;62:1875–83.
34. Jassal JV, Opeltz G, Cole E. Transplantation in the elderly: a review. 
Geriatr Nephrol Urol 1997;7:157–65.
